Thermo Fisher Scientific (NYSE:TMO) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other equities analysts have also commented on TMO. Barclays upped their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective for the company. Royal Bank Of Canada increased their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Finally, Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $628.78.

Thermo Fisher Scientific Stock Up 0.5%

Shares of NYSE:TMO opened at $655.49 on Friday. The company’s fifty day moving average is $618.62 and its two-hundred day moving average is $534.71. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific has a 1-year low of $435.27 and a 1-year high of $683.63. The stock has a market capitalization of $242.37 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 2.74 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the business posted $4.28 EPS. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 over the last ninety days. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently modified their holdings of the company. Tsfg LLC lifted its position in Thermo Fisher Scientific by 20.4% during the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock worth $56,000 after purchasing an additional 19 shares during the period. Renasant Bank raised its position in shares of Thermo Fisher Scientific by 1.0% in the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after buying an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. lifted its holdings in shares of Thermo Fisher Scientific by 5.4% during the 1st quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock worth $212,000 after acquiring an additional 22 shares during the period. Legacy Wealth Managment LLC ID boosted its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Finally, Chesapeake Wealth Management increased its stake in Thermo Fisher Scientific by 0.6% in the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company’s stock valued at $1,868,000 after acquiring an additional 22 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.